Paul L Berns
CIK 1202769 · See Remarks · last filed 2026-08-21
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
KARD price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
260 ARSENAL PLACE, SUITE 1
WATERTOWN, MA 02472
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| NMRA | See Remarks | 7,528,282 | $0.35 | $2.63M | -$57.9K | 8 | 2026-08-21 |
| KARD | Director | 15,062,741 | $12.74 | $191.90M | $20.00M | 2 | 2026-06-24 |
| LYEL | 10%+ Owner | 1,426,528 | $13.62 | $19.44M | $12.50M | 1 | 2026-03-09 |
| Metsera, Inc. (MTSR) Delisted | Director | 0 | $70.50 | $0 | $14.22M | 3 | 2025-11-13 |
| Unity Biotechnology, Inc. (UBX) Delisted | Director | 326 | $0.20 | $65 | $0 | 7 | 2024-06-21 |
| EQRx, Inc. (EQRXW) Delisted | Director | 0 | $0.05 | $0 | $0 | 4 | 2023-11-09 |
| JAZZ | Director | 8,290 | $234.93 | $1.95M | -$3.76M | 23 | 2021-08-09 |
| VYNE Therapeutics Inc. (MNLO) Delisted | Director | — | — | — | $0 | 2 | 2019-08-08 |
| Anacor Pharmaceuticals, Inc. (ANAC) Delisted | President and CEO | 0 | $10.19 | $0 | -$16.52M | 14 | 2016-06-24 |
| XENOPORT INC (XNPT) Delisted | Director | 15,000 | — | — | -$525.2K | 10 | 2016-05-19 |
| Cellectar Biosciences, Inc. (CLRB.Z) Delisted | Director | 117,371 | — | — | $248.8K | 1 | 2016-04-21 |
| Cellectar Biosciences, Inc. (CLRB.W) Delisted | Director | — | — | — | $0 | 2 | 2015-06-10 |
| ALLOS THERAPEUTICS INC (ALTH) Delisted | Chief Executive Officer | 0 | — | — | -$4.14M | 22 | 2012-09-05 |
Holdings By Holder
| Symbol | Holder | Shares | Share of Total | Reported |
|---|---|---|---|---|
| NMRA | Direct | 7,395,185 | 98.2% | 2026-02-19 |
| LULU TRUST OF 2024 FBO OB See footnote |
133,097 | 1.8% | 2026-02-19 | |
| Total | 7,528,282 | |||
| KARD | Direct | 20,706 | 0.1% | 2026-06-24 |
| By ARCH Venture Fund XIII, L.P. | 15,042,035 | 99.9% | 2026-06-24 | |
| Total | 15,062,741 | |||
| LYEL | ARCH Venture Fund IX, L.P. See footnote |
1,426,528 | 100.0% | 2026-03-09 |
| Total | 1,426,528 | |||
| MTSR | Direct | 0 | — | 2025-11-13 |
| ARCH Venture Fund XIII, L.P.("ARCH Venture Fund XIII") See footnote |
0 | — | 2025-11-13 | |
| Total | 0 |
Recent Filings · Page 8 of 11
101 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2012-01-18 | JAZZ | Disp (D) | −39,200 | $0 | EDGAR |
| 2012-01-13 | JAZZ | Mixed | +39,200 | $70 | EDGAR |
| 2011-11-17 | ALLOS THERAPEUTICS INC (ALTH) Delisted | Sell (S) | −32,267 | -$47.2K | EDGAR |
| 2011-11-08 | JAZZ | Grant (A) | — | $0 | EDGAR |
| 2011-05-12 | XENOPORT INC (XNPT) Delisted | Grant (A) | — | $0 | EDGAR |
| 2011-03-18 | ALLOS THERAPEUTICS INC (ALTH) Delisted | Exer (M) | +2,500 | $7.8K | EDGAR |
| 2011-03-14 | JAZZ | Grant (A) | — | $0 | EDGAR |
| 2011-03-02 | ALLOS THERAPEUTICS INC (ALTH) Delisted | Grant (A) | +345,942 | $0 | EDGAR |
| 2011-02-25 | ALLOS THERAPEUTICS INC (ALTH) Delisted | Sell (S) | −13,448 | -$43.2K | EDGAR |
| 2010-10-22 | ALLOS THERAPEUTICS INC (ALTH) Delisted | Grant (A) | +265,734 | $0 | EDGAR |
10b5-1: the filer ticked the box for trades made under a Rule 10b5-1 trading plan, which sets the sales (or buys) in advance, so they say less about the insider's view at the time than a discretionary trade. The plan's adoption date is shown when the filing's footnotes give it.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment, and an amended or cancelled notice is not listed. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes. Someone who is no longer an officer or director (or never was) files no Form 4, so for them a sale shows up only on a later notice, which lists the seller's sales from the 3 months before it. "No sale on file" means neither record shows one; a dash in Net $ means the value filed on the notice doesn't fit the stock's price (likely a typo).